

24 June 2026

To
BSE Limited,
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

Scrip Symbol: 543064

Dear Sir/Madam,

Sub: Clarification on Volume Movement

This is in reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and with respect to BSE Email ref no. L/SURV/ONL/PV/SG/ 2026-2027 / 182 dated 24 June 2026, seeking clarification on the increase in volume of the shares of the Company traded across the Exchanges in the recent past.

The Company confirms that there is no pending information and/or announcement which, in terms of Regulation 30 of the SEBI Listing Regulations is required to be disclosed to the Stock Exchanges and which, in our opinion, may have a bearing on the volume behaviour of the Company's scrip.

The Company has been regularly notifying all Unpublished Price Sensitive Information ("UPSI"), as and when required, in compliance with Regulation 30 and other applicable provisions of the SEBI Listing Regulations.

This above clarification may please be taken on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)


Sisir K. Mishra
Company Secretary & Compliance Officer



Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

